Iberdomide

Iberdomide
Identifiers
	IUPAC name (3S)-3-[7-[[4-(Morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;
CAS Number	1323403-33-3;
PubChem CID	67335295;
IUPHAR/BPS	9618;
DrugBank	DB12101;
ChemSpider	52085251;
UNII	8V66F27X44;
KEGG	D11134;
ChEMBL	ChEMBL3989927;
Chemical and physical data
Formula	C25H27N3O5
Molar mass	449.507 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5;
	InChI InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1; Key:IXZOHGPZAQLIBH-NRFANRHFSA-N;

Iberdomide (CC-220) is an experimental thalidomide analog^[1] that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers^[2]^[3]^[4]^[5]^[6]^[7]^[8] and was also tested in people with lupus.^[9]

Quick Facts Identifiers, CAS Number ...

Iberdomide has been tested in combination with Bi-specific T-cell engagers in the B-Cell Non-Hodgkin Lymphoma setting,^[10] but has been dropped in favor of Golcadomide (CC-99282).

References